Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

CartiHeal

Request full access

Privately-held medical device company that develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints

Kfar Saba, IsraelFounded 2009Biotech & Life Sciences

About CartiHeal

CartiHeal is an Israeli medical device company focused on developing and commercializing proprietary implants for treating cartilage and osteochondral defects in knee joints, addressing both traumatic and osteoarthritic conditions. Founded in 2009 by Nir Altschuler as a spin-out from Ben-Gurion University of the Negev, the company operates from Kfar Saba, Israel, with a sales office in New Jersey.

The company's core product is the Agili-C implant, a single-stage, off-the-shelf solution for knee cartilage and osteochondral defects. The implant is a cell-free, biocompatible, and resorbable scaffold made from aragonite, a natural form of calcium carbonate derived from coral. This porous, bi-phasic implant is designed to promote the regeneration of both the original articular cartilage and the underlying subchondral bone. The body gradually absorbs the implant over time, allowing new, healthy tissue to take its place.

CartiHeal targets a significant market, including the approximately 700,000 patients in the US who undergo cartilage repair annually. Its technology is notable for its broad indication, which includes patients with mild to moderate osteoarthritis, a demographic previously lacking effective treatment options. The business model centers on the sale of this implant to orthopedic surgeons and healthcare facilities for use in a single-step surgical procedure.

A key milestone was achieved in March 2022, when the Agili-C implant received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA), following a 'Breakthrough Device Designation' in 2020. This approval was based on a major clinical study involving 251 patients, which demonstrated the superiority of Agili-C over the existing standard of care, such as microfracture and debridement. In January 2024, the global medical technology company Smith & Nephew completed its acquisition of CartiHeal for an initial consideration of $180 million, with potential for up to an additional $150 million based on sales performance. This acquisition integrated Agili-C into Smith & Nephew's sports medicine portfolio.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2009
Headquarters
Kfar Saba, Israel
Employees
17
Open positions
None listed
Dealroom signal
72.2/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Rehabilitation, Biotechnology, medical implants, Biodegradable, Regenerative Medicine, Spinout, Tech for Patients, Biotech and Pharma, DT and LS
Business model
Manufacturing
Client focus
B2C

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Nov 2023 $330M $330M Smith & Nephew ↗
ACQUISITIONOther financing Sep 2021 $315M — Bioventus —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

CartiHeal website traffic

Latest recorded traffic for CartiHeal is 620 monthly website visits, down 86.2% over the last three months. CartiHeal's team declined 32% over the past year.

Latest monthly visits620 3-month web change-86.2% 1-year team growth-32%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

CartiHeal in the Kfar Saba ecosystem

Live from Dealroom

The CartiHeal office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Johnson & Johnson Innovation
  • Access Medical Ventures
  • Elron
  • Peregrine Ventures

Series B and later2 investors entered at this stage

  • aMoon Fund
  • Bioventus

Other known investors2 additional known investors

  • Ben-Gurion University of the Negev
  • Smith & Nephew
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇮🇱 Israel92.9%
🇺🇸 United States7.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about CartiHeal on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See CartiHeal’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.